Q-omics provides the consensus-scored LRATD2 profile across patient tissues and cancer cell-line models. LRATD2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRATD2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, LRATD2 RNA expression shows 19,845 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where LRATD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRATD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRATD2 survival associations across molecular data types. LRATD2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRATD2 RNA expression–survival associations across cancer types. High LRATD2 expression shows unfavorable associations in UCEC and PAAD, but favorable associations in KIRC, LGG, STAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRATD2 RNA expression.
This table summarizes LRATD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRATD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRATD2 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, BLCA, STAD and THCA. The COAD box plot shows higher LRATD2 RNA expression in tumor versus normal tissue (log2 FC = +1.107, t-test p < 0.001).
This table shows molecular features associated with LRATD2 in patient tissues and cancer cell lines. In patient samples, LRATD2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRATD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
